133 related articles for article (PubMed ID: 34856873)
41. [Evaluation of the enhanced International Prognostic Index (NCCN-IPI) for cases with diffuse large B-cell lymphoma].
Yamada A; Tamura H; Asayama T; Moriya K; Okuyama N; Kondo-Onodera A; Hamada Y; Ishibashi M; Yokose N; Tanosaki S; Inokuchi K
Rinsho Ketsueki; 2015 Jul; 56(7):915-8. PubMed ID: 26256931
[TBL] [Abstract][Full Text] [Related]
42. Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients.
Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
Med Oncol; 2017 Feb; 34(2):29. PubMed ID: 28083854
[TBL] [Abstract][Full Text] [Related]
43. Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.
Han Y; Yang J; Liu P; He X; Zhang C; Zhou S; Zhou L; Qin Y; Song Y; Sun Y; Shi Y
Oncologist; 2019 Nov; 24(11):e1251-e1261. PubMed ID: 30952824
[TBL] [Abstract][Full Text] [Related]
44. How I manage patients with grey zone lymphoma.
Kritharis A; Pilichowska M; Evens AM
Br J Haematol; 2016 Aug; 174(3):345-50. PubMed ID: 27301470
[TBL] [Abstract][Full Text] [Related]
45. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
[TBL] [Abstract][Full Text] [Related]
46. Interim
Jiang M; Chen P; Ruan X; Ye X; Pan Y; Zhang J; Huang Q; Zhou W; Wu H; Wang Q
Oncol Lett; 2017 Dec; 14(6):6715-6723. PubMed ID: 29344120
[TBL] [Abstract][Full Text] [Related]
47. [Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma].
Liu W; Wang X; Zhang C; Xie Y; Lin N; Tu M; Ping L; Ying Z; Deng L; Huang H; Wu M; Sun Y; Du T; Leng X; Ding N; Zheng W; Song Y; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):269-72. PubMed ID: 27093984
[TBL] [Abstract][Full Text] [Related]
48. [Efficacy of additional two cycles of rituximab administration for patients with diffuse large B-cell lymphoma in first remission].
Zhong HJ; Xu PP; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):756-761. PubMed ID: 27719717
[TBL] [Abstract][Full Text] [Related]
49. Disease characteristics of diffuse large B-cell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience.
Gaut D; Romero T; Oveisi D; Howell G; Schiller G
Hematol Oncol; 2020 Feb; 38(1):38-50. PubMed ID: 31674036
[TBL] [Abstract][Full Text] [Related]
50. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
51. [Analysis of survival and prognosis in 409 newly diagnosed patients with diffuse large B-cell lymphoma].
Wen J; Zhou J; Liu Z; Liu T; Xu C
Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):318-24. PubMed ID: 24759020
[TBL] [Abstract][Full Text] [Related]
52. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.
Troppan KT; Schlick K; Deutsch A; Melchardt T; Egle A; Stojakovic T; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Pichler M
Br J Cancer; 2014 Jul; 111(1):55-60. PubMed ID: 24874478
[TBL] [Abstract][Full Text] [Related]
53. Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma.
Hong J; Kim SJ; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Lee HS; Yun HJ; Lee SI; Kim MK; Yi JH; Lee JH; Kim WS; Suh C
Oncotarget; 2017 Nov; 8(54):92171-92182. PubMed ID: 29190906
[TBL] [Abstract][Full Text] [Related]
54. Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a clinicopathological study of 14 Epstein-Barr virus-positive cases.
Elsayed AA; Satou A; Eladl AE; Kato S; Nakamura S; Asano N
Histopathology; 2017 Mar; 70(4):579-594. PubMed ID: 27735994
[TBL] [Abstract][Full Text] [Related]
55. Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI.
Melchardt T; Troppan K; Weiss L; Hufnagl C; Neureiter D; Tränkenschuh W; Schlick K; Huemer F; Deutsch A; Neumeister P; Greil R; Pichler M; Egle A
J Natl Compr Canc Netw; 2015 Dec; 13(12):1501-8. PubMed ID: 26656519
[TBL] [Abstract][Full Text] [Related]
56. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
[TBL] [Abstract][Full Text] [Related]
57. MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
Wang J; Zhou M; Xu JY; Yang YG; Zhang QG; Zhou RF; Chen B; Ouyang J; Li C
Histol Histopathol; 2016 Mar; 31(3):285-92. PubMed ID: 26424560
[TBL] [Abstract][Full Text] [Related]
58. Retrospective Analysis of a New Prognostic Score for Diffuse Large B-Cell Lymphoma Based on Interim Positron Emission Tomography-Computed Tomography.
Liu T; Chen L; Pan J; Pan L; Hu J; Ji Z
Acta Haematol; 2018; 139(3):148-157. PubMed ID: 29550822
[TBL] [Abstract][Full Text] [Related]
59. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
Prochazka KT; Melchardt T; Posch F; Schlick K; Deutsch A; Beham-Schmid C; Weiss L; Gary T; Neureiter D; Klieser E; Greil R; Neumeister P; Egle A; Pichler M
Br J Cancer; 2016 Nov; 115(10):1264-1272. PubMed ID: 27764838
[TBL] [Abstract][Full Text] [Related]
60. Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma.
Kanemasa Y; Shimoyama T; Sasaki Y; Hishima T; Omuro Y
Ann Hematol; 2018 Jun; 97(6):999-1007. PubMed ID: 29427185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
